Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma

17 Aug 2024

Abstract excerpt

Neuroblastoma (NBL) cells highly express disialoganglioside GD2, which is restricted and weakly expressed in selected healthy cells, making it a desirable target of immunotherapy. Over the past two decades, application of dinutuximab, an anti-GD2 monoclonal antibody (mAb), has been one of the few new therapies to substantially improve outcomes to current levels. Given the persistent challenge of relapse and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39199637
DOI: 10.3390/cancers16162865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaPMID 39199637Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

State of the Art in Immunotherapy of NeuroblastomaSemantic proximity Read ↗

Biological Insight and Recent Advancement in the Treatment of NeuroblastomaSemantic proximity Read ↗

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read ↗

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity Read ↗

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> miceSemantic proximity Read ↗

Tumor Microenvironment in Neuroblastoma and Immunotherapeutic Approaches: Towards More Effective TreatmentSemantic proximity Read ↗

Exploring and Targeting the Tumor Immune Microenvironment of NeuroblastomaSemantic proximity Read ↗

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read ↗

Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk NeuroblastomaSemantic proximity Read ↗

Gangliosides and NeuroblastomasSemantic proximity Read ↗

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.